Abstract
Structure-based rational design has been considered as a promising approach to design novel proteins. For this purpose, we designed artificial anticoagulant proteins that are able to target Factor Xa (FXa) using a functional motifgrafting approach. The motif corresponded to the residues Cys15 to Cys42 of Ancylostoma caninum anticoagulant peptide 5 (AcAP5), a potent FXa inhibitor. By screening of the Protein Data Bank (PDB) using Vector Alignment Search Tool (VAST, search for three-dimensional scaffolds in protein structures), we screened scaffolds as hosts to reproduce the functional topology of this motif. Three designed artificial chimeric proteins were expressed and purified to test their FXainhibiting ability. One of the recombinant proteins, pep3, was found to inhibit FXa with strong activity (IC50 of 152 nM) in vitro. Moreover, pep3 inhibited arterial thrombosis formation in rats with uniform potency compared with natural AcAP5. Therefore, our data demonstrate that motif-grafting is a useful tool to engineer novel artificial anticoagulant proteins.
Keywords: AcAP5, anticoagulant, Factor Xa, inhibitor, motif-grafting, VAST.
Protein & Peptide Letters
Title:Engineering Novel Anticoagulant Proteins by Motif Grafting
Volume: 21 Issue: 2
Author(s): Yuanjun Zhu, Aihua Liu, Xiaoyan Liu and Yinye Wang
Affiliation:
Keywords: AcAP5, anticoagulant, Factor Xa, inhibitor, motif-grafting, VAST.
Abstract: Structure-based rational design has been considered as a promising approach to design novel proteins. For this purpose, we designed artificial anticoagulant proteins that are able to target Factor Xa (FXa) using a functional motifgrafting approach. The motif corresponded to the residues Cys15 to Cys42 of Ancylostoma caninum anticoagulant peptide 5 (AcAP5), a potent FXa inhibitor. By screening of the Protein Data Bank (PDB) using Vector Alignment Search Tool (VAST, search for three-dimensional scaffolds in protein structures), we screened scaffolds as hosts to reproduce the functional topology of this motif. Three designed artificial chimeric proteins were expressed and purified to test their FXainhibiting ability. One of the recombinant proteins, pep3, was found to inhibit FXa with strong activity (IC50 of 152 nM) in vitro. Moreover, pep3 inhibited arterial thrombosis formation in rats with uniform potency compared with natural AcAP5. Therefore, our data demonstrate that motif-grafting is a useful tool to engineer novel artificial anticoagulant proteins.
Export Options
About this article
Cite this article as:
Zhu Yuanjun, Liu Aihua, Liu Xiaoyan and Wang Yinye, Engineering Novel Anticoagulant Proteins by Motif Grafting, Protein & Peptide Letters 2014; 21 (2) . https://dx.doi.org/10.2174/092986652102131226112049
DOI https://dx.doi.org/10.2174/092986652102131226112049 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Recent Advances Towards Drug Design Targeting the Protease of 2019 Novel Coronavirus (2019-nCoV)
Current Medicinal Chemistry Withdrawal Notice: Emerging Novel Coronavirus is a Global Threat: Insight in the Biology of COVID-19 and its Hijacking Process of Hosts’ Cell
Current Pharmaceutical Design Persistent Hiccups as an Atypical Initial Presentation of COVID-19: A Case Report
Infectious Disorders - Drug Targets COVID-19 in People with Diabetes: Perspectives from Saudi Arabia
Current Diabetes Reviews Can Host Cell Proteins Like ACE2, ADAM17, TMPRSS2, Androgen Receptor be the Efficient Targets in SARS-CoV-2 Infection?
Current Drug Targets A Comparative Analysis of Protein Interfaces
Protein & Peptide Letters COVID-19: Are Experimental Drugs a Cure or Cause?
Current Drug Safety Traditional Medicine - A Possible Stop Codon for COVID-19
Current Traditional Medicine A Mini Review: Origin, Treatments, Preventions, Real Facts and Viability of the Recent Pandemic of Novel Coronavirus-2019
Coronaviruses Hydroxychloroquine, Arbidol and COVID-19: The Jury is Still Out!
Current Respiratory Medicine Reviews Role of Cations in the Interaction of Pradimicins with HIV-1 Envelope gp120
Current Topics in Medicinal Chemistry Point of Care Ultrasound in Coronavirus 2019: Helpful or Not?
Current Respiratory Medicine Reviews WITHDRAWAL NOTICE: Review of the Times When One-Third of the Mankind is Under Lockdown Due to Coronavirus
Coronaviruses Coronavirus (COVID-19) and Employee Health
Coronaviruses Boosting Innate Immunity During SARS-CoV-2 Clearance
Coronaviruses Graphical Representations of Protein Sequences for Alignment-Free Comparative and Predictive Studies. Recognition of Protease Inhibition Pattern from H-Depleted Molecular Graph Representation of Protease Sequences
Current Bioinformatics Promiscuous Biological Features of Newly Emerged SARS-CoV-2 Facilitate its Unrestrained Outbreak: An Update
Coronaviruses Phenolics Constituents of Different Types of Propolis and their Antimicrobial Activities
Anti-Infective Agents Severe Community-Acquired Pneumonia (CAP) due to Atypical Pathogens
Current Respiratory Medicine Reviews Targeting HIV-1 gp41 in Close Proximity to the Membrane Using Antibody and Other Molecules
Current Topics in Medicinal Chemistry